Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 weeks

Hepatitis C virus (HCV) chronic infection is still a major public health problem. Recent estimations point to a global prevalence of 70 million people living with HCV chronic infection worldwide.1 Most untreated HCV-infected individuals may be soon concentrated in countries in South America, Africa, South-east Asia and Eastern Europe, because access to treatments has been more difficult in those areas, mainly due to cost issues.2 HIV infection is also highly prevalent in some specific countries of these regions3 and, in this way, both epidemics do overlap.

Source: Journal of Infection - May 13, 2019 Category: Infectious Diseases Authors: Ana ïs Corma-Gómez, Juan Macías, Dolores Merino MuñOZ, Francisco Téllez, Rafael Granados, Luis E. Morano, Ignacio De Los Santos Gil, Francisco J. Vera-Méndez, Antonio Collado, Rosario Palacios, Juan A. Pineda Source Type: research